²é¿´: 2503  |  »Ø¸´: 1

jinkairui123

Ìú³æ (ÕýʽдÊÖ)

[½»Á÷] CRISPR´¥·¢µÄÄÚÔ´Oct4»òSox2»ùÒòλµãȾɫÖÊÖØËܼ¤»îϸ°ûÖØ±à³Ì ÒÑÓÐ1È˲ÎÓë

ÌâÄ¿£ºCRISPR-Based Chromatin Remodeling of the Endogenous Oct4 or Sox2 Locus Enables
Reprogramming to Pluripotency
ÆÚ¿¯£ºCell stem cell
Ó°ÏìÒò×Ó£º23.394
Ö÷Òª¼¼Êõ£ºCRISPR-dCas9-VP64¼¤»îϵͳ¡¢ÓÕµ¼ÐÔ¶àÄܸÉϸ°û¹¹½¨¡¢Ô­´úϸ°ûÖÆ×÷¡¢iPS¼ø¶¨
Ñо¿±³¾°
       ÖÕÄ©·Ö»¯µÄ³ÉÌåϸ°ûÄæ·Ö»¯£¬ÐγɶàÄܸÉϸ°û״̬µÄ¹ý³Ì³ÆÎªÏ¸°ûÖØ±à³Ì£¨Cell reprogramming£©¡£ÔÚ2006Ä꣬ÈÕ±¾¿ÆÑ§¼ÒɽÖÐÉìÃÖ£¨Shinya Yamanaka£©·¢±íÓÕµ¼ÐÔ¶àÄܸÉϸ°û£¨iPS, induced pluripotent stem cells£©¹¹½¨¼¼Êõ£¬ÀûÓÃÄæ×ªÂ¼²¡¶¾£¬°ÑOSKM£¨OCT4, SOX2,KLF4 and C-myc£©ËÄÒò×ÓÔÚÌåϸ°ûÖнøÐ㬱í´ï£¬³É¹¦°ÑСÊóÅßÌ¥³ÉÏËάϸ°ûÓÕµ¼ÐγɶàÄܸÉϸ°û£¬¿ª±ÙÁËÒ»¸öȫеĸÉϸ°ûÑо¿ÁìÓò¡£Ëæ×ÅÑо¿µÄÉîÈ룬ÈËÆ¤·ô³ÉÏËάϸ°û¡¢TÁܰÍϸ°ûµÈÒ²±»³É¹¦ÓÕµ¼³É¶àÄܸÉϸ°û¡£¶øÕâЩ¶àÄܸÉϸ°ûÓ빩ÌåDNAÊDZ£³ÖÒ»Öµģ¬ÇÒÓзֻ¯³É¶àÖÖϸ°ûµÄDZÁ¦£¬Õ¹ÏÖ³ö·Ç³£¹ãÀ«µÄÁÙ´²Ó¦ÓÃǰ¾°¡£Èç°ÑÈËѪҺÖеÄTÁܰÍϸ°ûÄæ·Ö»¯ÐγɶàÄܸÉϸ°ûºó£¬µ±¶¨Ïò·Ö»¯¼¼Êõ³ÉÊìʱ£¬ iPSÄܱ»ÓÐÐò·Ö»¯³ÉÐèÒªµÄϸ°û£¬±ÈÈçÐļ¡Ï¸°û¡¢Éñ¾­Ï¸°ûµÈ¡£
       ȾɫÌåÉÏÖØÒªµÄ»ùÒòÆô¶¯×ÓλµãµÄ±í¹ÛÒÅ´«Ñ§±ä»¯£¬ÈçDNA¼×»ù»¯Ë®Æ½±ä»¯¡¢×éµ°°×ÒÒõ£»¯Ë®Æ½±ä»¯¡¢È¾É«ÖÊÖØËܵȣ¬¿ªÆôÖØÒª»ùÒòÈçOCT4, SOX2µÈµÄÄÚÔ´ÐÔ±í´ï£¬ÊÇiPSÓÕµ¼¹ý³ÌÖÐÖÁ¹ØÖØÒªµÄʼþ£¬Ö±½Ó¹ØÏµµ½ÓÕµ¼ÊÇ·ñ³É¹¦¡£
      CRISPR-Cas9ϵͳ×÷ΪһÖÖÇ¿´óµÄ»ùÒò±à¼­¹¤¾ß£¬ÏÖ½ñÒѹ㷺ÓÃÓÚ³£¹æµÄϸ°û»òÕ߸öÌåµÄ»ùÒòÇóý¡¢»ùÒòÇÃÈë¡¢µãÍ»±äÍâ¡£µ±CAS9µ°°×½øÐÐʧ»î¸ÄÔìÒÔ¼°½á¹¹ÓòÌí¼Óºó£¬µÃµ½CRISPR-dCas9-SunTag-VP64ϵͳ£¬ÔòÄÜʵÏÖÌØÒì»ùÒòת¼¼¤»î¡£CRISPR-dCas9ÄÚÔ´»ùÒò¼¤»î¼¼Êõ£¨SunTag Gene Activation£©£¬ÕýºÃÓëiPSÓÕµ¼¼¼ÊõÍêÃÀÆõºÏ£¬½â¾öÁ˼¤»îÄÚÔ´OSKMËÄ»ùÒòµÄÎÊÌ⣬´Ó¶øµ®ÉúÁËÐÂÐ͵ÄiPS¹¹½¨²ßÂÔ£¨¼ûͼ1£©¡£
         
ͼ1. ÀûÓÃCRIPR-dCas9»ùÒò¼¤»îϵͳµÄiPSÓÕµ¼²ßÂÔ                  

Ñо¿ÄÚÈݼ°½á¹û
1. Éè¼Æ¶¨Î»ÓÚSox2ºÍOct4»ùÒòÆô¶¯×ÓÇøºÍOct4ÔöÇ¿×ÓÇøµÄsgRNA£¬ÀûÓÃCRISPR-dCas9-SunTag-VP64¶ÔSox2ºÍOct4½øÐм¤»î¡£
       ±¾Ñо¿Ê×ÏÈÉè¼ÆÁËÏàÓ¦»ùÒò°Ð±êµÄSgRNA£¬Æô¶¯×ÓÇø»òÕßÔöÇ¿×ÓÇø°Ð±êλÖÿ¼ÂÇÒòËØ°üÀ¨£ºsgRNA°Ð±êλÖÃÓëÖØÒªµÄת¼Òò×Ó£¨OCT4¡¢SOX2¡¢NANOG£©½áºÏλµã¡¢×éµ°°×ÒÒõ£×ªÒÆÃ¸p300½áºÏλµãµÄ¾àÀ룬°Ð±êÇø¸½½ü×éµ°°×ÒÒõ£»¯·Ö²¼¡¢DNA¼×»ù»¯·Ö²¼µÈ¡£²¢ÒÔMEFϸ°ûΪ²ÄÁÏ£¬ÔÚRNAˮƽ¼ì²âÁ˲»Í¬sgRNA¶Ô°Ð±ê»ùÒòsox2ºÍoct4µÄ¼¤»îЧ¹û£¨Í¼2£©¡£

ͼ 2. MEFϸ°ûÖУ¬Sox2ºÍOct4»ùÒòÆô¶¯×ÓÇøºÍOct4ÔöÇ¿×ÓÇø²»Í¬sgRNAµÄת¼¼¤»îЧ¹ûÑé֤ʵÑé         

2. CRISPR-dCas9-SunTag-VP64ϵͳ¶ÔÖØÒª»ùÒò½øÐÐÄÚÔ´¼¤»î£¬Äܳɹ¦»ñµÃiPS.
       Ëæºó£¬Í¬ÑùʹÓô˷½·¨£¬ÀûÓÃɸѡ³öÀ´18¸öÓÐЧsgRNA£¬·Ö±ð¼¤»î7¸öÖØÒª»ùÒò: Oct4, Sox2, Klf4, c-Myc, Nr5a2, Glis 1, Cebpa¡£½«MEFÀûÓò¡¶¾¸ÐȾ·½·¨½øÐÐ18 sgRNAµ¼Èëºó£¬ÓëdCas9-SunTag-VP64Ðγɸ´ºÏÌ壬¼¤»îÁËOG2-MEFÖÐÏàÓ¦ÄÚÔ´»ùÒòµÄ±í´ï£¬¾­¹ý17ÌìµÄÓÕµ¼ºó£¬³É¹¦µÃµ½ÁËiPSϸ°û£¬²¢Îȶ¨´«´ú£¬ÇÒÏÔʾ³öÓëÅßÌ¥¸Éϸ°ûÏàͬµÄ¿Ë¡ÐÎ̬¡£Í¨¹ýÃâÒßÓ«¹âºÍQPCR£¬ÏÔʾµÃµ½µÄiPS±í´ïNanog, Sox2ºÍSSEA-1£¬Ïà¹Ø¸Éϸ°û»ùÒò±í´ïˮƽÓëRIÅßÌ¥¸Éϸ°ûÏà±È£¬¾ùÏ൱»òÕß³¬¹ý¡£´Ë²¿·ÖÖ¤Ã÷CRISPR-dCas9-SunTag-VP64ϵͳ½øÐÐÄÚÔ´¼¤»îʱ£¬Äܳɹ¦ÊµÏÖiPSÓÕµ¼£¨Í¼3£©¡£

ͼ3. CRISPR-dCas9-SunTag-VP64ϵͳͬʱ¼¤»îOct4, Sox2, Klf4, c-Myc, Nr5a2, Glis 1, CebpaÄÚÔ´±í´ïʱ£¬Äܳɹ¦ÊµÏÖiPSÓÕµ¼                           

3. CRISPR-dCas9-SunTag-VP64ϵͳµ¥¶À¶ÔSox2»ùÒò½øÐÐÄÚÔ´¼¤»î£¬Ò²ÄÜÓÐЧ»ñµÃiPS
       Ñо¿Õßµ¥¶ÀѡȡÁËÄܶÔSox2½øÐ줻îµÄSgRNA½øÐÐiPSÓÕµ¼£¬·¢ÏÖÔÚÓÐЧ¼¤»îÄÚÔ´Sox2»ùÒò±í´ïµÄÇé¿öÏ£¬Äܳɹ¦µÃµ½ÓÕµ¼ÐÔ¶àÄܸÉϸ°û£¬²¢ÄÜÎȶ¨ÔöÖ³´«´ú¡£µÃµ½iPSͨ¹ýÌåÄÚÌåÍâʵÑ飬Èç¸Éϸ°û»ùÒò±í´ïÇé¿ö¼ì²âʵÑ飨ÃâÒßÓ«¹â¡¢qPCRµÈ£©¡¢ÄÒÅß×¢ÉäʵÑéµÈ£¬ÔÚÄÒÅß×¢ÉäʵÑéºó£¬»¹µÃµ½ÁËǶºÏÌåСÊ󣬲¢ÄÜÎȶ¨µØÉúÖ³´«µÝ£¬ºó´úÖеõ½OG2СÊóƷϵµÄСÊó¡£ÕâЩʵÑéÖ¤Ã÷ÁËiPSϸ°ûϵµÄÍêÕû¸ÉÐÔ£ºÎȶ¨×ÔÎÒ¸üÐÂÄÜÁ¦ºÍ¶àÏò·Ö»¯ÄÜÁ¦£¨Í¼4£©¡£
                  
ͼ4. CRISPR-dCas9-SunTag-VP64ϵͳµ¥¶À¼¤»îSox2ÄÚÔ´±í´ïʱ£¬Äܳɹ¦ÊµÏÖiPSÓÕµ¼     

4. CRISPR-dCas9-SunTag-VP64ϵͳͬʱ¶ÔOct4»ùÒòÆô¶¯×ÓÇøºÍÔöÇ¿×ÓÇø½øÐÐÄÚÔ´¼¤»î£¬ÄÜÓÐЧ»ñµÃiPS
       ½ÓÏÂÀ´£¬Ñо¿Õßѡȡ°Ð±êλÖÃΪOct4Æô¶¯×ÓÇø»òÕßÔöÇ¿×ÓÇøµÄsgRNA½øÐÐÓÕµ¼ÊµÑ飬·¢ÏÖµ¥¶ÀÀûÓÃOct4Æô¶¯×ÓÇøµÄsgRNA»òÕßÔöÇ¿×ÓÇøsgRNA¶ÔOct4»ùÒò½øÐ줻îʱ£¬ËäÈ»±í´ï¼¤»î£¬µ«ÄÚÔ´Ç¿¶ÈÎÞ·¨µÃÓëÅßÌ¥¸Éϸ°ûϵR1Ïà±È¡£ÔÚÓÕµ¼¹ý³ÌÖУ¬µ¥¶ÀµÄsgRNAÎÞ·¨µÃµ½iPS¡£Oct4Æô¶¯×ÓÇøµÄsgRNA»òÕßÔöÇ¿×ÓÇøsgRNA½øÐÐ×éºÏʱ£¬ÄÚÔ´Oct4±í´ïÇ¿¶ÈµÃµ½Á˺ܺõÄÌáÉý£¬×îÖյõ½iPS£¬²¢ÄÜÎȶ¨ÔöÖ³´«´ú¡£µÃµ½iPSͨ¹ýÌåÄÚÌåÍâʵÑ飬Èç¸Éϸ°û»ùÒò±í´ïÇé¿ö¼ì²âʵÑ飨ÃâÒßÓ«¹â¡¢qPCRµÈ£©¡¢ÄÒÅß×¢ÉäʵÑéµÈ£¬ÔÚÄÒÅß×¢ÉäʵÑéºó£¬»¹µÃµ½ÁËǶºÏÌåСÊ󣬲¢ÄÜÎȶ¨µØÉúÖ³´«µÝ£¬ºó´úÖеõ½OG2СÊóƷϵµÄСÊó¡£ÕâЩʵÑéÖ¤Ã÷ÁËiPSϸ°ûϵµÄÍêÕû¸ÉÐÔ£ºÎȶ¨×ÔÎÒ¸üÐÂÄÜÁ¦ºÍ¶àÏò·Ö»¯ÄÜÁ¦£¨Í¼5£©¡£
                   
ͼ 5. CRISPR-dCas9-SunTag-VP64ϵͳͬʱ¶ÔOct4»ùÒòÆô¶¯×ÓÇøºÍÔöÇ¿×ÓÇø½øÐÐÄÚÔ´¼¤»îÄÜÓÐЧ»ñµÃiPS                                         

ÎÄÕÂС½á
       ×÷ΪÀûÓÃCRISPR-dCas9¼¤»îϵͳ½øÐÐiPS¹¹½¨£¬×÷Õ߷dz£ÓÐÁ¦µØÖ¤Ã÷ÁËCRISPR-dCas9-SunTag-VP64ϵͳ¶Ô¹¹½¨iPSµÄÓÐЧÐÔ¡£¿ÉÒÔÔ¤¼û£¬ºóÐøµÄMEFÖ±½ÓÓÕµ¼ÐγÉÐļ¡Ï¸°û¡¢Éñ¾­Ï¸°ûµÄÑо¿ÖУ¬´ËϵͳºÜ¿ÉÄÜÒ²ÓÐһϯ֮µØ¡£´ËÎÄÕ¼ȽøÐÐÁËÏà¹Ø¼¼Êõ·½·¨Ì½Ë÷£¬Ò²»Ø´ðÁËÒ»¸ö·Ç³£ºÃµÄ¿ÆÑ§ÎÊÌ⣺iPSÓÕµ¼¹ý³ÌÖУ¬Ïà¹ØÄÚÔ´»ùÒòµÄ±í¹ÛÒÅ´«Ñ§±ä»¯Ö±¹ÛÖØÒª¡£
       ÔÚ±í¹ÛÒÅ´«Ñ§Ñо¿ÖУ¬CRIPSR-dCas9¼¤»îÄÚÔ´»ùÒò±í´ïµÄÓ¦Ó㬻áÏà¶Ô¹ã·ºÒ»Ð©¡£CRISPR-dCas9-SunTag-VP64ϵͳÉԼӸĽø£¬ºÜ¿ÉÄÜÊÇÖ±½Ó¸Ä±äÏà¹Ø»ùÒò±í¹ÛÒÅ´«Ñ§ÌØÕ÷µÄÀûÆ÷¡£

½âÎöÎÄÏ×
P. Liu, M. Chen, Y. Liu, L.S. Qi, S. Ding. CRISPR-Based Chromatin Remodeling of the Endogenous Oct4 or Sox2 Locus Enables Reprogramming to Pluripotency, Cell stem cell, 22 (2018) 252-261.


²Î¿¼ÎÄÏ×
1. Black, J. B., Adler, A. F., et al. (2016) Targeted Epigenetic Remodeling of Endogenous Loci by CRISPR/Cas9-Based Transcriptional Activators Directly Converts Fibroblasts to Neuronal Cells. Cell stem cell 19, 406-414
2Chakraborty, S., Ji, H., Kabadi, A. M., et al. (2014) A CRISPR/Cas9-based system for reprogramming cell lineage specification. Stem cell reports 3, 940-947
3. Chavez, A., Scheiman, J., et al. (2015) Highly efficient Cas9-mediated transcriptional programming. Nature methods 12, 326-328
4. Thakore, P. I., D'Ippolito, A. M., et al. (2015) Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nature methods 12, 1143-1149
5. Buganim, Y., Faddah, D. A., et al. (2012) Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. Cell 150, 1209-1222
6.Takahashi, K., and Yamanaka, S. (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676
»Ø¸´´ËÂ¥
Î人½ð¿ªÈðÉúÎÌṩºËËáºÍµ°°×µÄÕûÌåÑо¿·½°¸
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

xjjf

Í­³æ (³õÈëÎÄ̳)

ºÜÀ÷º¦Ñ½
2Â¥2021-07-31 23:50:57
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌø×ª ÎÒÒª¶©ÔÄÂ¥Ö÷ jinkairui123 µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] Ò»Ö¾Ô¸Î÷ÄϽ»Í¨ ר˶ ²ÄÁÏ355 ±¾¿ÆË«·Ç Çóµ÷¼Á +4 Î÷ÄϽ»Í¨×¨²Ä355 2026-03-19 4/200 2026-03-20 11:39 by »¨¿ª¸»¹óÐÒ¸£ÈËÉ
[¿¼ÑÐ] ¡¾¿¼Ñе÷¼Á¡¿»¯Ñ§×¨Òµ 281·Ö£¬Ò»Ö¾Ô¸ËÄ´¨´óѧ£¬³ÏÐÄÇóµ÷¼Á +6 ³Ô³Ô³Ô²ÅÓÐÒâÒå 2026-03-19 6/300 2026-03-20 10:47 by ¾¡Ë´Ò¢1
[¿¼ÑÐ] 0856µ÷¼Á£¬ÊÇѧУ¾ÍÈ¥ +7 sllhht 2026-03-19 8/400 2026-03-20 09:30 by ÿÌìÖ»°ÚһС»á
[¿¼ÑÐ] 0817 »¯Ñ§¹¤³Ì 299·ÖÇóµ÷¼Á ÓпÆÑо­Àú ÓжþÇøÎÄÕ +20 rare12345 2026-03-18 20/1000 2026-03-20 08:42 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] Ò»Ö¾Ô¸ËÕÖÝ´óѧ²ÄÁÏÇóµ÷¼Á£¬×Ü·Ö315£¨Ó¢Ò»£© +3 sbdksD 2026-03-19 3/150 2026-03-19 23:21 by fmesaito
[¿¼ÑÐ] 307Çóµ÷¼Á +9 ÀäóÏ123 2026-03-17 9/450 2026-03-19 22:44 by ѧԱ8dgXkO
[¿¼²©] ¶«»ªÀí¹¤´óѧ»¯²Äרҵ26½ì˶ʿ²©Ê¿ÉêÇë +8 zlingli 2026-03-13 8/400 2026-03-19 16:32 by ÇáËɲ»ÉÙËæ
[¿¼ÑÐ] 286Çóµ÷¼Á +6 lemonzzn 2026-03-16 10/500 2026-03-19 14:31 by lemonzzn
[¿¼ÑÐ] Ò»Ö¾Ô¸ Î÷±±´óѧ £¬070300»¯Ñ§Ñ§Ë¶£¬×Ü·Ö287£¬Ë«·ÇÒ»±¾£¬Çóµ÷¼Á¡£ +3 ³¿»èÏßÓëÐǺ£ 2026-03-19 3/150 2026-03-19 13:36 by houyaoxu
[¿¼ÑÐ] Ò»Ö¾Ô¸¸£´ó288Óлú»¯Ñ§£¬Çóµ÷¼Á +3 Сľ³æ200408204 2026-03-18 3/150 2026-03-19 13:31 by houyaoxu
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á£¬Çó¸÷λÀÏʦÊÕÁô +10 ÇïÓÐľ±± 2026-03-14 10/500 2026-03-19 05:52 by anny19840123
[¿¼ÑÐ] ÊÕ¸´ÊÔµ÷¼ÁÉú +4 ÓêºóÇïºÉ 2026-03-18 4/200 2026-03-18 14:16 by elevennnne
[¿¼ÑÐ] ÉúÎïѧ071000 329·ÖÇóµ÷¼Á +3 ÎÒ°®ÉúÎïÉúÎﰮΠ2026-03-17 3/150 2026-03-18 10:12 by macy2011
[¿¼ÑÐ] 326Çóµ÷¼Á +5 Éϰ¶µÄСÆÏ 2026-03-15 6/300 2026-03-17 17:26 by ruiyingmiao
[¿¼ÑÐ] 308Çóµ÷¼Á +4 ÊÇLupa°¡ 2026-03-16 4/200 2026-03-17 17:12 by ruiyingmiao
[ÂÛÎÄͶ¸å] ÓÐûÓдóÀз¢Ð¡ÂÛÎÄÄÜ´øÎÒ¸ö¶þ×÷ +3 ÔöÈñ©ÈË 2026-03-17 4/200 2026-03-17 09:26 by xs74101122
[¿¼ÑÐ] 278Çóµ÷¼Á +3 Yy7400 2026-03-13 3/150 2026-03-17 08:24 by laoshidan
[¿¼ÑÐ] 297Ò»Ö¾Ô¸ÉϽ»085600Çóµ÷¼Á +5 Ö¸¼â°ËǧÀï 2026-03-14 5/250 2026-03-14 17:26 by a²»Ò×
[¿¼ÑÐ] 297Çóµ÷¼Á +4 ѧº£Æ¯²´ 2026-03-13 4/200 2026-03-14 11:51 by ÈÈÇéɳĮ
[¿¼ÑÐ] 266Çóµ÷¼Á +4 ѧԱ97LZgn 2026-03-13 4/200 2026-03-14 08:37 by zhukairuo
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û